Retatrutide, CagriSema and Emerging Treatments Retatrutide, CagriSema, survodutide, MariTide, VK2735, eloralintide and other next-generation treatments remain investigational for routine obesity care as of July 2026
No Impact on IGF-1 or Blood Sugar Levels Unlike full growth hormone therapy, which can increase IGF-1 and affect glucose metabolism, AOD-9604: Does not elevate IGF-1 levels, reducing the risk of unwanted anabolic effects or organ enlargement
10mg vial of lyophilized powder
Dietary changes also help
Most realize that steady, incremental tweaks to daily habits, rather than a hot pursuit of quick fixes, maintain results long-term
The new generation of weight loss drugs: The pros and cons of GLP-1s The University of Kentucky Public Relations and Strategic Communications Office provides a weekly health column available for use and reprint by news media